Ex vivo expansion of natural killer cells for clinical applications.
about
Natural Killer Cells for Therapy of LeukemiaNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityImproving the outcome of leukemia by natural killer cell-based immunotherapeutic strategiesMembrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cellsHigh log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapyManufacturing Natural Killer Cells as Medicinal Products"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer ImmunotherapyClinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture processEx vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.A new avenue to cure cancer by turning adaptive immune T cells to innate immune NK cells via reprogramming.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transferNatural killer cells: can they be useful as adoptive immunotherapy for cancer?Immune restoration following hematopoietic stem cell transplantation: an evolving target.Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigensBiological response modifiers as adjuncts to stem cell transplantation.Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells.Expansion and activation of natural killer cells for cancer immunotherapy.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.Novel cord blood transplant therapies.Stimulating natural killer cells to protect against cancer: recent developments.Natural killer cells: a review of manufacturing and clinical utility.Clinical grade purification and expansion of natural killer cells.Expansion, purification, and functional assessment of human peripheral blood NK cells.NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21.Advances in clinical NK cell studies: Donor selection, manufacturing and quality controlMembrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation.Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma.Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.Influence of autologous dendritic cells on the in-vitro expansion and functions of peripheral blood NK cells.Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
P2860
Q26745906-EBE96A64-60AF-4D8B-BF6C-73F0A1CF4E64Q26773135-C2A4CBC4-89AE-41BC-AF64-0085DDA55B51Q26996660-CC5BB2D2-D427-4256-87A6-3E2A5EB69894Q27309991-471A263C-5D0C-45A6-A3F2-9AC32915F14DQ27334458-7E1202FD-95DB-4D6E-855F-581F765BEE0BQ28069992-EADFE369-75EA-4B12-84CC-60B6AAFC39E5Q28081338-F9483790-AEB3-4BA1-B104-4144C9C3D4B9Q28743568-7FF5A5E0-BC18-4E29-A271-AFC9E4EFE442Q33861833-0E8139F0-E9B6-4B80-9304-0CBFD29847F3Q34187231-A0C0C3D0-3BC0-4EDD-BDA6-82CBF12DDD4BQ35600095-9F6B0287-ECC2-4C6F-B692-9FE7E653FF7AQ35799180-626C983E-ADFD-4E9F-82FE-78604B1C8E7FQ36065944-08304F97-9832-4A40-AFD5-D5E26256AADEQ36075296-858B28B2-5602-4AF6-9D03-07E4E0012D6BQ36163212-68923D2C-5E85-4FD2-AC63-D6D23A53745EQ36377047-00A71B2C-EDDC-4DCF-B2F1-F8B398ECE7EFQ36446933-2D8FBA25-548C-4260-9382-9050446304E9Q36453570-B8D37480-C5BB-428A-A929-2A734EDCE5A4Q36676064-88628B09-EE54-4ED1-A569-7206BD656195Q37357114-82EE5CA2-20D1-4406-A5B9-A67ECEE32BFCQ37408279-A80E5B64-D0A9-4E93-9622-F67A0FFA4FF9Q37565475-C3196674-4628-4ABF-A1F7-C68CF1C8038CQ37785538-06FD09FF-052B-4986-BB1E-7F73BF0EB024Q37800641-CDA0EFE6-DCD8-4DE9-9877-07810CC0AAFEQ37877269-0B32C57C-BD5A-4DAF-9F50-74449350F440Q38016470-6FEDBCBB-D222-47DE-B1DC-01F4ECD342F3Q38221228-6974CDC0-D241-44EE-A564-16DBD66EEA2BQ38568681-14B244D7-642E-4273-80B5-B3AF16C9E98CQ38631020-3FCB1F32-4BED-490B-9001-00E3C94068BEQ38766781-A93FBA6A-1CB8-4725-A611-8DE5BB9BBB76Q38771096-B695E2DC-9038-4922-8AE1-2136D1959DFCQ38824360-22DA4E5D-7098-463D-B5F2-9C73C98A585CQ39182404-D2707172-CD8E-4856-8D68-D1FEE5A68BCAQ39525496-827C8236-3D49-497F-8BE8-A09FF1C2706BQ39679501-8C33A868-6ADF-4C06-B070-0718D7E5135BQ40507101-3C94C1D5-4FAE-466E-8928-E4943A70B2E4Q41298062-7B02533E-55DE-4B64-95A9-4EA6F5F7A719Q51034109-566DFD8E-12D8-4AC2-AE20-DFA2F271E5AFQ54667188-5BE59FCD-599F-4D1B-B3CB-E78CC5987832
P2860
Ex vivo expansion of natural killer cells for clinical applications.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Ex vivo expansion of natural killer cells for clinical applications.
@en
Ex vivo expansion of natural killer cells for clinical applications.
@nl
type
label
Ex vivo expansion of natural killer cells for clinical applications.
@en
Ex vivo expansion of natural killer cells for clinical applications.
@nl
prefLabel
Ex vivo expansion of natural killer cells for clinical applications.
@en
Ex vivo expansion of natural killer cells for clinical applications.
@nl
P1433
P1476
Ex vivo expansion of natural killer cells for clinical applications.
@en
P2093
Klingemann HG
Martinson J
P356
10.1080/14653240310004548
P577
2004-01-01T00:00:00Z